UPCC 03423: A Phase 1b/2a Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia

Age
99 years or below
Gender
All
Location
1

Brief description of study

This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia. We would like to rely on Advarra as the IRB of record for this study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 12 Apr 2023. Study ID: 853243
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research